SCHEMBL16808697

SCHEMBL16808697

CCCCOC[C@H]1OC(C)(C)O[C@H]1c1ccccc1Cl

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.34
LMNA P02545 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.33
OPRL1 P41146 2/20 0.33
GAA P10253 2/20 0.33
TSHR P16473 2/20 0.33
MAPT P10636 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
USP2 O75604 1/20 0.33
POLB P06746 1/20 0.33
ALOX15 P16050 1/20 0.33
HSD17B10 Q99714 1/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
KDM1A O60341 1/20 0.33
RCOR1 Q9UKL0 1/20 0.33
HTR2A P28223 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18179364 1.00 ALDH1A1 (0.34) ALDH1A1LMNASMN1; SMN2OPRL1GAA
SCHEMBL16808556 1.00 ALDH1A1 (0.34) ALDH1A1LMNASMN1; SMN2OPRL1GAA
SCHEMBL16808656 0.82 SMN1; SMN2 (0.37) ALDH1A1LMNASMN1; SMN2GAATSHR
SCHEMBL16808546 0.82 SMN1; SMN2 (0.37) ALDH1A1LMNASMN1; SMN2GAATSHR
SCHEMBL29418611 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR
SCHEMBL17119535 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR
SCHEMBL15551716 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR
SCHEMBL17093315 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR
SCHEMBL29015095 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR
SCHEMBL29418820 0.82 TAAR1 (0.37) ALDH1A1LMNAOPRL1GAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9834535-B2 Sulfamate derivative compounds for use in treating or alleviating pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2017-12-05 US disclosed
EP-2861571-B1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO LTD (KR) 2017-05-03 EP disclosed
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-11-03 US disclosed
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy BIO-PHARM SOLUTIONS CO., LTD. (KR) 2016-10-27 US disclosed
US-9221783-B2 Phenylalkyl sulfamate compound and muscle relaxant composition comprising the same BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-12-29 US disclosed
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME BIO-PHARM SOLUTIONS CO., LTD. (KR) 2015-09-24 US disclosed
WO-2015088273-A9 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-08-06 WO disclosed
WO-2015088273-A1 SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN BIO-PHARM SOLUTIONS, CO., LTD. (KR) 2015-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160318894-A1 Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain SULT2A1, STS, SULT1A1 ALDH1A1 920/4885LMNA 4820/4885SMN1; SMN2 427/4885
US-20150266848-A1 PHENYLALKYL SULFAMATE COMPOUND AND MUSCLE RELAXANT COMPOSITION COMPRISING THE SAME MYLK, MUSK, MYLK2 ALDH1A1 3249/4885LMNA 1666/4885SMN1; SMN2 317/4885
US-20160310461-A1 Sulfamate Derivative Compound for Use in Preventing or Treating Epilepsy STS, SULT2A1, GRIK5 ALDH1A1 649/4885LMNA 4336/4885SMN1; SMN2 910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.